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Correspondence

Patients with immune-mediated inflammatory diseases (IMID)
have largely been excluded in clinical trials of SARS-
CoV-2
mRNA vaccines due to both disease status and immunotherapeutics used. A recent study by Geisen et al has shown that patients
with IMID using immunotherapeutics exhibited significantly
lower antibody titres against the SARS-CoV-2 spike protein (S)
after full vaccination with a SARS-CoV-2 mRNA vaccine relative to vaccinated healthy controls (HCs), suggesting a compromised SARS-CoV-2 mRNA vaccine antibody response in this
population.1 Furthermore, a separate study by Boyarsky et al
found that a proportion of patients with IMID with or without
immunomodulatory therapy failed to seroconvert after the first
dose with a SARS-
CoV-2 mRNA vaccine.2 Here, we quantified SARS-CoV-2 mRNA vaccine-induced anti-S and receptor-
binding domain (RBD) antibodies among fully vaccinated HCs
and found that antibody levels in patients with IMID using
immunotherapeutics were significantly lower than HCs.
A total of 66 HCs and 8 patients with IMID who had been
fully vaccinated (BNT162b2 or mRNA-1273) for at least 2 weeks
were recruited. All participants received their first vaccination
between 13 December 2020 and 5 February 2021 and the second
dose between 3 January 2021 and 5 March 2021. Individuals
with known prior SARS-CoV-2 infection were excluded. IMID
diagnoses included psoriasis, rheumatoid arthritis, systemic lupus
erythematosus (SLE), mixed connective tissue disease, hidradenitis suppurativa and inflammatory bowel disease. All patients
with IMID were on an immunomodulatory therapy, including
biologic and non-
biologic disease-
modifying antirheumatic
drug therapy, corticosteroid or combination therapy (table 1).
Demographic information is detailed in online supplemental
table S1. Additionally, non-vaccinated non-convalescent healthy
individuals (n=8) were included as controls. Fully quantitative
anti-
SARS-
CoV-2 immunoglobulin G (IgG) antibodies were
measured with the COVID-SeroIndex ELISA kit (Kantaro and
Bio-Techne, USA), assessing both anti-S and RBD antibodies.3

Table 1 Patient-level IMID diagnosis, immunotherapeutic regimen
and anti-S IgG level
Anti-S IgG
Immunotherapeutic regimen (AU/mL)

Age

Sex

IMID diagnosis

30s

F

HS and LCV

Tofacitinib

16.4

40s

F

Ulcerative colitis

Infliximab and azathioprine

52.0

50s

F

RA

Hydroxychloroquine
Methotrexate

102.8

60s

F

SLE

60s

M

Psoriasis and PsA Ixekizumab

84.8

60s

F

RA, SLE and
MCTD

Mycophenolate

214.1

60s

F

SLE

Methotrexate and prednisone
5 mg

120.9

60s

F

RA and SLE

Prednisone 5 mg

Undetectable

90.5

anti-S, anti-spike protein; HS, hidradenitis suppurativa; IgG, immunoglobulin G;
IMID, immune-mediated inflammatory disease; LCV, leukocytoclastic vasculitis;
MCTD, mixed connective tissue disease; PsA, psoriatic arthritis; RA, rheumatoid
arthritis; SLE, systemic lupus erythematosus.

Figure 1 Patients with IMID treated with immunotherapeutics
have reduced levels of SARS-CoV-2 vaccine-induced antibody. (A)
Semiquantitave anti-RBD IgG levels were measured in 66 HCs and 8
IMID patients who had been fully vaccinated for at least 2 weeks. Non-
vaccinated healthy participants were included as controls (n=8). The
red dashed line (0.7 CI) indicates the cut-off threshold correlating to the
presence or the absence of antibody per manufacturer (Kantaro and
Bio-Techne). Individuals with RBD levels above the 0.7 cut-off threshold
moved forward for anti-S IgG quantification. (B) Fully quantitative anti-S
IgG levels were measured in the study population: healthy: <50 years
old (n=55), healthy: ≥50 years old (n=11), IMID (n=8) and control (n=8).
Individuals with RBD levels below the 0.7 cut-off level were assigned
a value of 0. The red dashed line (25 AU/mL) indicates the threshold
correlating to 100% neutralising antibody levels per manufacturer.
Horizontal black bars indicate mean IgG levels. Unpaired two-tailed
t-test. *p<0.05; ****p<0.0001. Anti-S, anti-spike protein; CI, cut-off
index; HCs, healthy controls; IgG, immunoglobulin G; IMID, immune-
mediated inflammatory diseases; RBD, receptor-binding domain.
As expected, all vaccinated HCs achieved seroconversion
(anti-RBD positive), which is in line with clinical trial results
from mRNA-12735 and BNT162b2.6,4 5 while one patient
with IMID and all non-vaccinated non-convalescent HCs were
below the detectable limit (figure 1A). Given a mean age of 55.9
years (range: 33–68 years) among patients with IMID, HCs
were split into groups of less than 50 years of age (mean age:
34.4 years (range: 21–49 years); n=55) and 50 years or older
(mean age: 56.4 years (range: 50–66 years); n=11). Anti-S-IgG
antibody levels were comparable between the <50-year-old and
≥50-year-old HC groups (p=0.19), with a mean of 178.7 AU/
mL (95% CI, 163 to 194) and 153.8 AU/mL (95% CI, 114 to
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194), respectively (figure 1B). Antibody levels among patients
with IMID were significantly lower (85.2 AU/mL (95% CI, 29
to 141)) compared with two HC groups, suggesting a compromised vaccine-induced antibody response among patients with
IMID (figure 1B). IMID patient-level demographics, diagnosis,
immunotherapeutics regimen and individual anti-S-IgG antibody
levels are outlined in table 1. One patient with SLE on low-dose
prednisone failed to seroconvert, and one patient with hidradenitis suppurativa on tofacitinib had an anti-S-IgG level below the
threshold of 25 AU/mL correlating to 100% neutralising antibody level.
Our study reveals that fully vaccinated patients with IMID
using immunotherapeutic regimens had significantly lower levels
of anti-S antibody relative to HCs, extending Geisen et al’s findings1 that patients with IMID using immunotherapeutics produce
lower titres of vaccine-induced anti-SARS-CoV-2 antibodies. In
contrast to Giesen et al, where all patients with IMID had seroconversion after full vaccination, we observed one patient with
IMID who did not mount a detectable antibody response after
full vaccination, which was also suggested by Boyarsky et al,2
although after only a single vaccination. While most patients
with IMID did mount a detectable anti-S antibody response after
full vaccination, it remains unknown how much protection this
provides or if the response is durable. Limitations of the current
study and Geisen et al’s findings1 include a relatively small
sample size and the absence of extended longitudinal measurements. Further investigation using greater numbers of patients
with IMID and specific immunotherapeutic regimens will be
required to assess antibody levels longitudinally and characterise
SARS-CoV-2 memory B cell and T cell responses. These data
are urgently needed to plan effective vaccination approaches for
patients with IMID, including when and if booster doses will
be required and if holding certain immunotherapeutics before
and after vaccination may be necessary to achieve a meaningful
correlate of protection.

